AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02543177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prior kidney irrigation
Study NCT02126553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02126553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02086487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg.
Description: Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg once a day but are determined to be sub-optimally responding to Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg BID and then will be assessed for therapy response. ELN guidelines 2013 for imatinib therapy response states as:~Minor cytogenetic response mCyR or minimal response at 3 months (Ph+ metaphases in BM 35 to 95 %); BCR-ABL1 transcript > 10% at 3 months; Partial cytogenetic response at 6 months Ph+ metaphases in BM 0to 35); BCR-ABL1 transcript is 1 to 10% at 6 months. Less than a major molecular response at > 12 months; i.e (BCR-ABL1 0.1 -1%)
Study NCT03070171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: single dose
Study NCT01734954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic nerve anesthesia blockade at bifurcation.
Description: A proximal and distal initial scan and define the site to block the bifurcation. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% and a total volume of 20 mL.
Study NCT01734954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic nerve blockade 2 cm beyond the bifurcation
Description: A proximal and distal initial scan and define the sites to block: tibial and peroneal nerves separate distal 2 cm from the bifurcation site. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% 10 mL tibial nerve and 10 mL to the peroneal nerve.
Study NCT01734954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5%: 20 ml
Description: Levobupivacaine is a local anesthetic that is commonly use for anesthesia nerve blockade.
Study NCT01734954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable Ultrasound Machine: Sonosite, M-Turbo, Bothell, WA
Description: An ultrasound machine is a device that is widely used for the correct placement of the local anesthetic for anesthesia nerve blockade.
Study NCT01734954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulated Needle, (Stimuplex; Braun, Melsungen, Germany)
Description: This is a specific kind of needle that is widely used for anesthesia nerve blockade.
Study NCT01734954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: supplemental oxygen
Description: supplemental oxygen during the block and/or during surgery
Study NCT01734954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Intravenous midazolam for sedation during the block and/or during surgery
Study NCT01734954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous analgesics
Description: Intraoperative administration intravenous of dipyrone 30-50 mg/Kg and or intravenous ketoprofen 100 mg or diclofenac 75 mg or ketorolac 30 mg
Study NCT01734954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saphenous nerve block
Description: Depending on sensitive territory committed by the type of surgery suprapatellar saphenous nerve block guided by ultrasound with 100 mm Stimuplex needle and injection of levobupivacaine 0.5% (total volume: 5 ml).
Study NCT02161094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Give incentives to physicians based on their patient's HbA1c improvement
Study NCT02161094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Give incentives to patients based on their own HbA1c improvement
Study NCT04286490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone position
Description: Abdomen suspension in prone position
Study NCT03587116 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care FIX Replacement therapy
Description: There is no investigational product being administered. Subjects will be administering their own standard of care FIX replacement therapy.
Study NCT03587116 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care FVIII Replacement therapy
Description: There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
Study NCT02362503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068
Study NCT02362503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-663068
Description: BMS-663068
Study NCT02362503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03709264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acids
Description: Patients randomized to experimental arm receive a continuous infusion of a balanced mixture of amino acids in a dose of 2 g/kg ideal body weight/day (to a maximum 100 g/day) from the operating room admission up to either death, start of RRT, ICU discharge or 72 hours after treatment initiation, trough a central venous line
Study NCT03709264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo: standard treatment
Study NCT01905800 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biaxial rotational chair
Description: This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.
Study NCT01905800 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Biaxial rotational chair
Description: This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.
Study NCT03477305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blackberry Consumption
Description: Measures of biomedical and behavioral changes resulting from the consumption of blackberries.
Study NCT03500523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: corneal biomechanical properties
Description: We want to investigate changes of corneal biomechanical properties during pregnancy. The Ocular Response Analyzer (ORA) evaluate the in vivo corneal biomechanical properties in form of corneal hysteresis (CH) and corneal resistance factor (CRF)
Study NCT03360838 — intervention group
Intervention type: OTHER
Intervention: CogCheck
Description: Performance of study participants in the application
Study NCT01874353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib 300mg tablets
Description: 300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
Study NCT01874353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match olaparib 300mg
Description: 300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
Study NCT01663454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Robomemo working memory training
Description: The Cogmed Robomemo program is designed as a computer game in which an animated robot gives different tasks to be solved by the child. The tasks have various degrees of difficulty adapted continuously throughout the intervention period to the performance of the individual child. The program is standardized in that each child receives the same set of tasks during the training period. The child will perform the training sessions at home using their own computer for about 35-40 minutes each day.
Study NCT01712620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Initial dose, 25 mg (pink capsule) orally, daily. If well tolerated at 7-9 wks then increased to 50 mg (brown capsule) daily.
Study NCT01712620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initial dose, pink sugar capsule, daily. If well tolerated at 7-9 wks then changed to brown sugar capsule, daily.
Study NCT01758549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aggressive Intravenous Hydration Group
Description: Patients in the intravenous hydration group wll be treated with lactated ringer infusion at a rate of 3cc/kg/hour during the procedure, be given a bolus of 20cc/kg immediately afterward and receive an infusion of 3cc/kg/hour for 8 hours after the procedure.
Study NCT01758549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Fluids Arm
Description: Patients randomized to the standard fluids arm will receive lactated ringers at an infusion rate of 1.5cc/kg/hour during the procedure, will receive no bolus, and will receive an infusion of lactated ringers at 1.5cc/kg for 8 hours after the procedure.
Study NCT03616015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: 20 to 30 ml of blood sample (D0, D15, D30, D60, D90, D180, Y1, Y2)
Study NCT03616015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal samples
Description: 1 g of feces (D-8, D0, D15, D30, D90)
Study NCT03616015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety test
Description: Test of Spielberger
Study NCT03616015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress test
Description: Test of Cohen
Study NCT03677037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-term MBT
Description: Short-term mentalization-based therapy
Study NCT03677037 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Long-term MBT
Description: Long-term mentalization-based therapy
Study NCT01473485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial System
Description: MR Guided Focused Ultrasound
Study NCT02169869 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirena
Description: A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
Study NCT02169869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirena
Description: A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
Study NCT02169869 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paragard
Description: A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
Study NCT02169869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paragard
Description: A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
Study NCT03792932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic distal pancreatectomy
Description: Laparoscopic distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
Study NCT03792932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open distal pancreatectomy
Description: Open distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
Study NCT00879710 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: simvastatin or ezetimibe
Description: Subjects will be started on either simvastatin or ezetimibe (we will alternate the subjects so that half the sample will initially be treated with simvastatin and half will be started on ezetimibe). The dose of Simvastatin (Merck) is 40 mg orally at nighttime for 6 weeks and the dose of ezetimibe (Schering-Plough) is 10 mg taken orally once a day. Subjects will be instructed on low-fat diet (therapeutic life style changes diet) recommended by American Heart Association by the bionutritionist.
Study NCT02131584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02131584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study NCT03575936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home INR Monitoring
Description: The self-monitoring group will monitor INR at home using the AlereTM Home Monitoring Service. They will call in the weekly results to Alere or submit online via the patient portal, which is the standard protocol among home monitoring patients. Alere will then upload the information to a password-protected HIPAA compliant website that only study investigators will be able to access. Pharmacists will have real-time access to the test results via the web interface. Pharmacists can follow up in real time if the patient forgets to self-test. An alert will also be sent to the pharmacists via email to follow up on any out of range results. This will help streamline pharmacists' workload to dedicate face-to-face time for patients that require such intervention. All home monitoring patients will be seen in clinic by the pharmacist at the end of the 3-month randomization period in order to assess compliance with meter-use and re-evaluate meter-use competency.
Study NCT03575936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The patients in the standard of care group will have a clinic visit with the pharmacist at least once every 4 weeks or earlier, as deemed necessary by the pharmacist. The duration of the randomization period will be three months. At the end of the 3-month randomization period, patients will be provided the opportunity to cross over from the home INR monitoring group to the pharmacist-managed clinic group, or vice versa. The remainder of the study duration (post-3 month analysis) will purely be for observational purposes, in order to account for the loss of randomization and potential bias. The total duration of the study will be one year.
Study NCT01854151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Labeling/Dosing Strategy
Description: Parents whose children are prescribed liquid medication will receive medications with health literacy informed labels and dosing instruments
Study NCT01053793 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glycemic response to different varieties of potatoes
Description: the glycemic response top 50g available carbohydrates from 4 potato varieties will be compared to a 50g glucose standard
Study NCT01053793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic response to different varieties of potatoes
Description: the glycemic response top 50g available carbohydrates from 4 potato varieties will be compared to a 50g glucose standard
Study NCT04124432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be smoked
Study NCT04124432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine will be smoked or vaporized
Study NCT01970553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurbinectedin (PM01183)
Description: lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials
Study NCT01970553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg vial, powder for injectable solution
Study NCT01964781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Topical administration - does it reduce surgical bleeding?
Study NCT01964781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Topical Bupivacaine- does it reduce surgical pain?
Study NCT01964781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline
Description: Topical adrenaline - does it reduce bleeding on its own, and does it enhance the effect of tranexamic acid?
Study NCT02791932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: See description above.
Study NCT01028768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: 10 mg, one-time subcutaneous
Study NCT01152619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4989991
Description: Subcutaneous repeated dose
Study NCT03575065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-290
Description: Administered orally
Study NCT01054560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOLITAIRE™ Device
Description: The SOLITAIRE™ Device is the experimental device that will be used in the interventional procedure
Study NCT01054560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MERCI® Device
Description: The MERCI® Device is the control device that will be used in the interventional procedure.
Study NCT01117298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tab Tadalafil, 20 mg alternate day for 8 weeks
Study NCT01117298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tab Placebo every alternate day for 8 weeks
Study NCT05213637 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Expanded Activated Lymphocytes (EAL)
Description: 12\~20 doses of EAL (1×10\^9\~2×10\^10 cells per dose) will be infused into patients.
Study NCT03584516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: In Part 1dose determination participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment. In Part 1 expansion, participants will receive either itacitinib administered orally either once daily or twice a day or corticosteroid alone based on the assigned treatment regimen according to cohort enrollment. In Part 2, participants will receive the recommended dose from Part 1 expansion.
Study NCT05213637 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transarterial chemoembolization (TACE)
Description: After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.
Study NCT03584516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itacitinib
Description: In Part 1dose determination participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment. In Part 1 expansion, participants will receive either itacitinib administered orally either once daily or twice a day or corticosteroid alone based on the assigned treatment regimen according to cohort enrollment. In Part 2, participants will receive the recommended dose from Part 1 expansion.
Study NCT03584516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Part 2, participants will receive matching placebo.
Study NCT03584516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
Study NCT05213637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization (TACE)
Description: After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.